Tumor hypoxia (English Wikipedia)

Natsuizaka M, Ozasa M, Darmanin S, Miyamoto M, Kondo S, Kamada S, et al. (September 2007). "Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia". Experimental Cell Research. 313 (15): 3337–48. doi:10.1016/j.yexcr.2007.06.013. hdl:2115/29921. PMID 17651733.
Capello M, Ferri-Borgogno S, Cappello P, Novelli F (April 2011). "α-Enolase: a promising therapeutic and diagnostic tumor target". The FEBS Journal. 278 (7): 1064–74. doi:10.1111/j.1742-4658.2011.08025.x. hdl:2318/87800. PMID 21261815.
Harada H (2011). "How can we overcome tumor hypoxia in radiation therapy?". Journal of Radiation Research. 52 (5): 545–56. Bibcode:2011JRadR..52..545H. doi:10.1269/jrr.11056. hdl:2433/148022. PMID 21952313.
van der Wiel AM, Jackson-Patel V, Niemans R, Yaromina A, Liu E, Marcus D, Mowday AM, Lieuwes NG, Biemans R, Lin X, Fu Z, Kumara S, Jochems A, Ashoorzadeh A, Anderson RF (2021-12-01). "Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506". Molecular Cancer Therapeutics. 20 (12): 2372–2383. doi:10.1158/1535-7163.MCT-21-0406. hdl:2292/64518. ISSN 1535-7163. PMC 9398139. PMID 34625504.

harvard.edu

ui.adsabs.harvard.edu

Vander Heiden MG, Cantley LC, Thompson CB (May 2009). "Understanding the Warburg effect: the metabolic requirements of cell proliferation". Science. 324 (5930): 1029–33. Bibcode:2009Sci...324.1029V. doi:10.1126/science.1160809. PMC 2849637. PMID 19460998.
Flier JS, Mueckler MM, Usher P, Lodish HF (March 1987). "Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes". Science. 235 (4795): 1492–5. Bibcode:1987Sci...235.1492F. doi:10.1126/science.3103217. PMID 3103217.
Harada H (2011). "How can we overcome tumor hypoxia in radiation therapy?". Journal of Radiation Research. 52 (5): 545–56. Bibcode:2011JRadR..52..545H. doi:10.1269/jrr.11056. hdl:2433/148022. PMID 21952313.

nih.gov

pubmed.ncbi.nlm.nih.gov

Gilkes DM, Semenza GL, Wirtz D (June 2014). "Hypoxia and the extracellular matrix: drivers of tumour metastasis". Nature Reviews. Cancer. 14 (6): 430–9. doi:10.1038/nrc3726. PMC 4283800. PMID 24827502.
Spill F, Reynolds DS, Kamm RD, Zaman MH (August 2016). "Impact of the physical microenvironment on tumor progression and metastasis". Current Opinion in Biotechnology. 40: 41–48. doi:10.1016/j.copbio.2016.02.007. PMC 4975620. PMID 26938687.
Vander Heiden MG, Cantley LC, Thompson CB (May 2009). "Understanding the Warburg effect: the metabolic requirements of cell proliferation". Science. 324 (5930): 1029–33. Bibcode:2009Sci...324.1029V. doi:10.1126/science.1160809. PMC 2849637. PMID 19460998.
Flier JS, Mueckler MM, Usher P, Lodish HF (March 1987). "Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes". Science. 235 (4795): 1492–5. Bibcode:1987Sci...235.1492F. doi:10.1126/science.3103217. PMID 3103217.
Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al. (July 2000). "Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc". The Journal of Biological Chemistry. 275 (29): 21797–800. doi:10.1074/jbc.C000023200. PMID 10823814.
Ezzeddini R, Taghikhani M, Somi MH, Samadi N, Rasaee, MJ (May 2019). "Clinical importance of FASN in relation to HIF-1α and SREBP-1c in gastric adenocarcinoma". Life Sciences. 224: 169–176. doi:10.1016/j.lfs.2019.03.056. PMID 30914315. S2CID 85532042.
Kanehisa M (2013). "Molecular Network Analysis of Diseases and Drugs in KEGG". Data Mining for Systems Biology. Methods in Molecular Biology. Vol. 939. pp. 263–75. doi:10.1007/978-1-62703-107-3_17. ISBN 978-1-62703-106-6. PMID 23192552.
Dang CV, Semenza GL (February 1999). "Oncogenic alterations of metabolism". Trends in Biochemical Sciences. 24 (2): 68–72. doi:10.1016/S0968-0004(98)01344-9. PMID 10098401. S2CID 18162447.
Zhang JZ, Behrooz A, Ismail-Beigi F (July 1999). "Regulation of glucose transport by hypoxia". American Journal of Kidney Diseases. 34 (1): 189–202. doi:10.1016/s0272-6386(99)70131-9. PMID 10401038.
Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, et al. (April 2001). "Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix". Clinical Cancer Research. 7 (4): 928–34. PMID 11309343.
Natsuizaka M, Ozasa M, Darmanin S, Miyamoto M, Kondo S, Kamada S, et al. (September 2007). "Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia". Experimental Cell Research. 313 (15): 3337–48. doi:10.1016/j.yexcr.2007.06.013. hdl:2115/29921. PMID 17651733.
Funasaka T, Yanagawa T, Hogan V, Raz A (September 2005). "Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia". FASEB Journal. 19 (11): 1422–30. doi:10.1096/fj.05-3699com. PMID 16126909. S2CID 45054626.
Ros S, Schulze A (February 2013). "Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism". Cancer & Metabolism. 1 (1): 8. doi:10.1186/2049-3002-1-8. PMC 4178209. PMID 24280138.
Lorentzen E, Siebers B, Hensel R, Pohl E (March 2005). "Mechanism of the Schiff base forming fructose-1,6-bisphosphate aldolase: structural analysis of reaction intermediates". Biochemistry. 44 (11): 4222–9. doi:10.1021/bi048192o. PMID 15766250.
Graven KK, McDonald RJ, Farber HW (February 1998). "Hypoxic regulation of endothelial glyceraldehyde-3-phosphate dehydrogenase". The American Journal of Physiology. 274 (2): C347-55. doi:10.1152/ajpcell.1998.274.2.C347. PMID 9486123.
Li H, Ko HP, Whitlock JP (August 1996). "Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF1alpha". The Journal of Biological Chemistry. 271 (35): 21262–7. doi:10.1074/jbc.271.35.21262. PMID 8702901.
Takahashi Y, Takahashi S, Yoshimi T, Miura T (June 1998). "Hypoxia-induced expression of phosphoglycerate mutase B in fibroblasts". European Journal of Biochemistry. 254 (3): 497–504. doi:10.1046/j.1432-1327.1998.2540497.x. PMID 9688259.
Capello M, Ferri-Borgogno S, Cappello P, Novelli F (April 2011). "α-Enolase: a promising therapeutic and diagnostic tumor target". The FEBS Journal. 278 (7): 1064–74. doi:10.1111/j.1742-4658.2011.08025.x. hdl:2318/87800. PMID 21261815.
Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, et al. (May 2011). "Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1". Cell. 145 (5): 732–44. doi:10.1016/j.cell.2011.03.054. PMC 3130564. PMID 21620138.
Filipp FV (2013). "Cancer metabolism meets systems biology: Pyruvate kinase isoform PKM2 is a metabolic master regulator". Journal of Carcinogenesis. 12: 14. doi:10.4103/1477-3163.115423. PMC 3746496. PMID 23961261.
Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL (January 2005). "Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma". Neoplasia. 7 (1): 1–6. doi:10.1593/neo.04373. PMC 1490315. PMID 15736311.
Kim JW, Dang CV (September 2006). "Cancer's molecular sweet tooth and the Warburg effect". Cancer Research. 66 (18): 8927–30. doi:10.1158/0008-5472.CAN-06-1501. PMID 16982728.
Serganova I, Rizwan A, Ni X, Thakur SB, Vider J, Russell J, et al. (October 2011). "Metabolic imaging: a link between lactate dehydrogenase A, lactate, and tumor phenotype". Clinical Cancer Research. 17 (19): 6250–6261. doi:10.1158/1078-0432.CCR-11-0397. PMC 4217119. PMID 21844011.
Chiche J, Ilc K, Laferrière J, Trottier E, Dayan F, Mazure NM, et al. (January 2009). "Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH". Cancer Research. 69 (1): 358–68. doi:10.1158/0008-5472.CAN-08-2470. PMID 19118021.
Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. (December 2008). "Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice". The Journal of Clinical Investigation. 118 (12): 3930–42. doi:10.1172/JCI36843. PMC 2582933. PMID 19033663.
Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. (May 2007). "Inhibitory effect of tumor cell-derived lactic acid on human T cells". Blood. 109 (9): 3812–9. doi:10.1182/blood-2006-07-035972. PMID 17255361. S2CID 2015271.
Beckert S, Farrahi F, Aslam RS, Scheuenstuhl H, Königsrainer A, Hussain MZ, Hunt TK (2006). "Lactate stimulates endothelial cell migration". Wound Repair and Regeneration. 14 (3): 321–4. doi:10.1111/j.1743-6109.2006.00127.x. PMID 16808811. S2CID 30136711.
Stern R (August 2008). "Hyaluronidases in cancer biology". Seminars in Cancer Biology. 18 (4): 275–80. doi:10.1016/j.semcancer.2008.03.017. PMID 18485730.
Sattler UG, Mueller-Klieser W (November 2009). "The anti-oxidant capacity of tumour glycolysis". International Journal of Radiation Biology. 85 (11): 963–71. doi:10.3109/09553000903258889. PMID 19895273. S2CID 33215098.
Gort EH, Groot AJ, van der Wall E, van Diest PJ, Vooijs MA (February 2008). "Hypoxic regulation of metastasis via hypoxia-inducible factors". Current Molecular Medicine. 8 (1): 60–7. doi:10.2174/156652408783565568. PMID 18289014.
Cárdenas-Navia LI, Mace D, Richardson RA, Wilson DF, Shan S, Dewhirst MW (July 2008). "The pervasive presence of fluctuating oxygenation in tumors". Cancer Research. 68 (14): 5812–9. doi:10.1158/0008-5472.CAN-07-6387. PMID 18632635.
DeBerardinis RJ (November 2008). "Is cancer a disease of abnormal cellular metabolism? New angles on an old idea". Genetics in Medicine. 10 (11): 767–77. doi:10.1097/GIM.0b013e31818b0d9b. PMC 2782690. PMID 18941420.
Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC (December 1953). "The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy". The British Journal of Radiology. 26 (312): 638–48. doi:10.1259/0007-1285-26-312-638. PMID 13106296.
Harada H (2011). "How can we overcome tumor hypoxia in radiation therapy?". Journal of Radiation Research. 52 (5): 545–56. Bibcode:2011JRadR..52..545H. doi:10.1269/jrr.11056. hdl:2433/148022. PMID 21952313.
Schlaff CD, Krauze A, Belard A, O'Connell JJ, Camphausen KA (March 2014). "Bringing the heavy: carbon ion therapy in the radiobiological and clinical context". Radiation Oncology. 9 (1): 88. doi:10.1186/1748-717X-9-88. PMC 4002206. PMID 24679134.
Bentzen SM, Gregoire V (April 2011). "Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription". Seminars in Radiation Oncology. 21 (2): 101–10. doi:10.1016/j.semradonc.2010.10.001. PMC 3052283. PMID 21356478.
Busk M, Overgaard J, Horsman MR (November 2020). "Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions". Seminars in Nuclear Medicine. 50 (6): 562–583. doi:10.1053/j.semnuclmed.2020.05.003. PMID 33059825. S2CID 222822277.
Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, et al. (January 2015). "Imaging tumour hypoxia with positron emission tomography". British Journal of Cancer. 112 (2): 238–50. doi:10.1038/bjc.2014.610. PMC 4453462. PMID 25514380.
Khan R, Seltzer M (August 2020). "PET Imaging of Tumor Hypoxia in Head and Neck Cancer: A Primer for Neuroradiologists". Neuroimaging Clinics of North America. 30 (3): 325–339. doi:10.1016/j.nic.2020.05.003. PMID 32600634. S2CID 220272658.
Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (October 1996). "Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix". Cancer Research. 56 (19): 4509–15. PMID 8813149.
Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, et al. (April 2008). "Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study". The Lancet. Oncology. 9 (4): 342–51. doi:10.1016/S1470-2045(08)70076-7. PMID 18343725.
Brown JM, Wilson WR (June 2004). "Exploiting tumour hypoxia in cancer treatment". Nature Reviews. Cancer. 4 (6): 437–47. doi:10.1038/nrc1367. PMID 15170446. S2CID 3105010.
Ahn GO, Brown M (May 2007). "Targeting tumors with hypoxia-activated cytotoxins". Frontiers in Bioscience. 12 (8–12): 3483–501. doi:10.2741/2329. PMID 17485316.
McKeown SR, Cowen RL, Williams KJ (August 2007). "Bioreductive drugs: from concept to clinic". Clinical Oncology. 19 (6): 427–42. doi:10.1016/j.clon.2007.03.006. PMID 17482438.
van der Wiel AM, Jackson-Patel V, Niemans R, Yaromina A, Liu E, Marcus D, Mowday AM, Lieuwes NG, Biemans R, Lin X, Fu Z, Kumara S, Jochems A, Ashoorzadeh A, Anderson RF (2021-12-01). "Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506". Molecular Cancer Therapeutics. 20 (12): 2372–2383. doi:10.1158/1535-7163.MCT-21-0406. hdl:2292/64518. ISSN 1535-7163. PMC 9398139. PMID 34625504.
Gainer JL, Sheehan JP, Larner JM, Jones DR (February 2017). "Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme". Journal of Neurosurgery. 126 (2): 460–466. doi:10.3171/2016.3.JNS152693. PMID 27177177.
Almoustafa HA, Alshawsh MA, Chik Z (August 2021). "Targeted polymeric nanoparticle for anthracycline delivery in hypoxia-induced drug resistance in metastatic breast cancer cells". Anti-Cancer Drugs. 32 (7): 745–754. doi:10.1097/CAD.0000000000001065. PMID 33675612. S2CID 232135776.

ncbi.nlm.nih.gov

Gilkes DM, Semenza GL, Wirtz D (June 2014). "Hypoxia and the extracellular matrix: drivers of tumour metastasis". Nature Reviews. Cancer. 14 (6): 430–9. doi:10.1038/nrc3726. PMC 4283800. PMID 24827502.
Spill F, Reynolds DS, Kamm RD, Zaman MH (August 2016). "Impact of the physical microenvironment on tumor progression and metastasis". Current Opinion in Biotechnology. 40: 41–48. doi:10.1016/j.copbio.2016.02.007. PMC 4975620. PMID 26938687.
Vander Heiden MG, Cantley LC, Thompson CB (May 2009). "Understanding the Warburg effect: the metabolic requirements of cell proliferation". Science. 324 (5930): 1029–33. Bibcode:2009Sci...324.1029V. doi:10.1126/science.1160809. PMC 2849637. PMID 19460998.
Ros S, Schulze A (February 2013). "Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism". Cancer & Metabolism. 1 (1): 8. doi:10.1186/2049-3002-1-8. PMC 4178209. PMID 24280138.
Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, et al. (May 2011). "Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1". Cell. 145 (5): 732–44. doi:10.1016/j.cell.2011.03.054. PMC 3130564. PMID 21620138.
Filipp FV (2013). "Cancer metabolism meets systems biology: Pyruvate kinase isoform PKM2 is a metabolic master regulator". Journal of Carcinogenesis. 12: 14. doi:10.4103/1477-3163.115423. PMC 3746496. PMID 23961261.
Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL (January 2005). "Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma". Neoplasia. 7 (1): 1–6. doi:10.1593/neo.04373. PMC 1490315. PMID 15736311.
Serganova I, Rizwan A, Ni X, Thakur SB, Vider J, Russell J, et al. (October 2011). "Metabolic imaging: a link between lactate dehydrogenase A, lactate, and tumor phenotype". Clinical Cancer Research. 17 (19): 6250–6261. doi:10.1158/1078-0432.CCR-11-0397. PMC 4217119. PMID 21844011.
Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. (December 2008). "Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice". The Journal of Clinical Investigation. 118 (12): 3930–42. doi:10.1172/JCI36843. PMC 2582933. PMID 19033663.
DeBerardinis RJ (November 2008). "Is cancer a disease of abnormal cellular metabolism? New angles on an old idea". Genetics in Medicine. 10 (11): 767–77. doi:10.1097/GIM.0b013e31818b0d9b. PMC 2782690. PMID 18941420.
Schlaff CD, Krauze A, Belard A, O'Connell JJ, Camphausen KA (March 2014). "Bringing the heavy: carbon ion therapy in the radiobiological and clinical context". Radiation Oncology. 9 (1): 88. doi:10.1186/1748-717X-9-88. PMC 4002206. PMID 24679134.
Bentzen SM, Gregoire V (April 2011). "Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription". Seminars in Radiation Oncology. 21 (2): 101–10. doi:10.1016/j.semradonc.2010.10.001. PMC 3052283. PMID 21356478.
Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, et al. (January 2015). "Imaging tumour hypoxia with positron emission tomography". British Journal of Cancer. 112 (2): 238–50. doi:10.1038/bjc.2014.610. PMC 4453462. PMID 25514380.
van der Wiel AM, Jackson-Patel V, Niemans R, Yaromina A, Liu E, Marcus D, Mowday AM, Lieuwes NG, Biemans R, Lin X, Fu Z, Kumara S, Jochems A, Ashoorzadeh A, Anderson RF (2021-12-01). "Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506". Molecular Cancer Therapeutics. 20 (12): 2372–2383. doi:10.1158/1535-7163.MCT-21-0406. hdl:2292/64518. ISSN 1535-7163. PMC 9398139. PMID 34625504.

sciencedirect.com

Ezzeddini R, Taghikhani M, Somi MH, Samadi N, Rasaee, MJ (May 2019). "Clinical importance of FASN in relation to HIF-1α and SREBP-1c in gastric adenocarcinoma". Life Sciences. 224: 169–176. doi:10.1016/j.lfs.2019.03.056. PMID 30914315. S2CID 85532042.

semanticscholar.org

api.semanticscholar.org

Ezzeddini R, Taghikhani M, Somi MH, Samadi N, Rasaee, MJ (May 2019). "Clinical importance of FASN in relation to HIF-1α and SREBP-1c in gastric adenocarcinoma". Life Sciences. 224: 169–176. doi:10.1016/j.lfs.2019.03.056. PMID 30914315. S2CID 85532042.
Dang CV, Semenza GL (February 1999). "Oncogenic alterations of metabolism". Trends in Biochemical Sciences. 24 (2): 68–72. doi:10.1016/S0968-0004(98)01344-9. PMID 10098401. S2CID 18162447.
Funasaka T, Yanagawa T, Hogan V, Raz A (September 2005). "Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia". FASEB Journal. 19 (11): 1422–30. doi:10.1096/fj.05-3699com. PMID 16126909. S2CID 45054626.
Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. (May 2007). "Inhibitory effect of tumor cell-derived lactic acid on human T cells". Blood. 109 (9): 3812–9. doi:10.1182/blood-2006-07-035972. PMID 17255361. S2CID 2015271.
Beckert S, Farrahi F, Aslam RS, Scheuenstuhl H, Königsrainer A, Hussain MZ, Hunt TK (2006). "Lactate stimulates endothelial cell migration". Wound Repair and Regeneration. 14 (3): 321–4. doi:10.1111/j.1743-6109.2006.00127.x. PMID 16808811. S2CID 30136711.
Sattler UG, Mueller-Klieser W (November 2009). "The anti-oxidant capacity of tumour glycolysis". International Journal of Radiation Biology. 85 (11): 963–71. doi:10.3109/09553000903258889. PMID 19895273. S2CID 33215098.
Busk M, Overgaard J, Horsman MR (November 2020). "Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions". Seminars in Nuclear Medicine. 50 (6): 562–583. doi:10.1053/j.semnuclmed.2020.05.003. PMID 33059825. S2CID 222822277.
Khan R, Seltzer M (August 2020). "PET Imaging of Tumor Hypoxia in Head and Neck Cancer: A Primer for Neuroradiologists". Neuroimaging Clinics of North America. 30 (3): 325–339. doi:10.1016/j.nic.2020.05.003. PMID 32600634. S2CID 220272658.
Brown JM, Wilson WR (June 2004). "Exploiting tumour hypoxia in cancer treatment". Nature Reviews. Cancer. 4 (6): 437–47. doi:10.1038/nrc1367. PMID 15170446. S2CID 3105010.
Almoustafa HA, Alshawsh MA, Chik Z (August 2021). "Targeted polymeric nanoparticle for anthracycline delivery in hypoxia-induced drug resistance in metastatic breast cancer cells". Anti-Cancer Drugs. 32 (7): 745–754. doi:10.1097/CAD.0000000000001065. PMID 33675612. S2CID 232135776.

worldcat.org

search.worldcat.org

van der Wiel AM, Jackson-Patel V, Niemans R, Yaromina A, Liu E, Marcus D, Mowday AM, Lieuwes NG, Biemans R, Lin X, Fu Z, Kumara S, Jochems A, Ashoorzadeh A, Anderson RF (2021-12-01). "Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506". Molecular Cancer Therapeutics. 20 (12): 2372–2383. doi:10.1158/1535-7163.MCT-21-0406. hdl:2292/64518. ISSN 1535-7163. PMC 9398139. PMID 34625504.